## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	paten	t app	plication of:	)	D 0 4 D 4				
Alex	ander	L. K	libanov et al.	)	Before the Examiner UNKNOWN				
App	licatio	n No	5. 10/511,383	)	Group Art Unit				
Filed	l May	18, 2	2005	)	1644				
MIC MET	ROBU HOD	JBB: S FC	LE COMPOSITIONS, AND DR PREPARING AND USING SAME	)	Confirmation No. 5031				
			INFORMATION DISCLOSUE	RE S	STATEMENT				
Çom PO E	3ox 14	oner 50	for Patents A 22313-1450						
1.	List of All Patents, Publications, U.S. Applications, or Other Information								
	Pursuant to the provisions of 37 CFR 1.56, 1.97, and 1.98, Applicant requests consideration of the references listed on the attached PTO/SB/08 form(s) (commonly referred to as a PTO-1449 form) and/or the additional information identified below.								
2.	Enc	lose	d Legible Copies						
	2a.		egible copy of each foreign patent docum D/SB/08 form is enclosed,	nent	t and publication listed on the				
		i.	except, a copy is <u>not</u> provided for each submitted to the Patent Office in prior temperature, filed claims priority under 35 U.S.C. §120.	U.S.					
		ii.	except, a copy is <u>not</u> provided for each reference identified below:	cun	nulative reference and enclosed				
	2b.		opy of the specification and drawings fo lication.	r ea	ch cited unpublished U.S.				

Information Disclosure Statement Serial No. 10/511,383 Attorney Docket: 22078-2 Page 1 of 4 # 439714

$\boxtimes$	2c.	A copy of a Search Report or Written Opinion from a foreign patent office is also enclosed.							
	2d.	Consideration of the enclosed additional and/or below discussed information is requested.							
<u>3.</u>	Con	cise Explanation of Relevance for Non-English Language Information							
For to:	each n	non-English language reference listed on the attached SB/08 form(s), reference is made							
	3a.	an English language translation submitted herewith,							
	3b.	foreign patent office Search Report (in the English language) submitted herewith,							
	3c.	an English language translation of a foreign patent office Search Report submitted herewith,							
	3d.	the concise explanation contained in the present application at page(s),							
	3e.	the concise explanation set forth in the attached English language abstract,							
	3f.	a copy of a related patent publication (in the English language) cited herewith,							
		Foreign Patent Document Corresponding English Language Patent Document							
	3g.	the following concise explanation:							
<u>4.</u>	Time	e for Filing							
$\boxtimes$	4a.	This Information Disclosure Statement is submitted:							
		<ul> <li>for U.S. national applications or national stage PCT applications (not including CPAs and RCEs), within 3 months of filing or entry into national stage; or</li> </ul>							
	$\boxtimes$	<ol> <li>for U.S. national applications, national stage PCT applications, CPAs or RCEs, before the first Office Action on the merits,</li> </ol>							
	and t	thus no certification and/or fee is required.							
	4b.	This information Disclosure Statement is submitted after three months from the filing date and after the first Office Action on the merits, but prior to the mailing date of a final Office Action or Notice of Allowance, and thus:							

		i.	the statement specified in 37 CFR §1.97(e) is provided below, or					
		ii.	a fee of \$ (set forth in 37 CFR §1.17(p)) is enclosed.					
	4c.	Off	This Information Disclosure Statement is submitted after the mailing date of a final Office Action or Notice of Allowance and prior to payment of the issue fee, and thus:					
		i.	the statement specified in 37 CFR §1.97(e) is provided below, <u>and</u> a fee of \$ (set forth in 37 CFR §1.17(p)) is enclosed, <u>or</u>					
		ii.	a Request for Continued Examination (RCE) and fee of 37 CFR §1.17(e) has been filed.					
	4d.		s Information Disclosure Statement is submitted after payment of the issue fee, thus:					
		i.	a Petition to Withdraw from Issue pursuant to 37 CFR §1.313(c)(2) has been filed, and					
		ii.	a Request for Continued Examination (RCE) and fee of 37 CFR §1.17(e) has been filed.					
<u>5.</u>	Certi	ficat	ion- Statement Under 37 CFR 1.97(e)					
	5a.	Dis offi	shereby certified that each item of information contained in this Information closure Statement was first cited in any communication from a foreign patent ce in a counterpart foreign application not more than three months prior to the ag of this Information Disclosure Statement.					
	5b.	the	opy of a dated communication from a foreign patent office which clearly shows statement is being submitted within three (3) months of the date on the amunication is enclosed.					
	5c.	Dis cou inq was	s hereby certified that no item of information contained in this Information closure Statement was cited in a communication from a foreign patent office in a interpart foreign application and, to my knowledge after making reasonable uiry, no item of information contained in this Information Disclosure Statement known to any individual designated in §1.56(c) more than three months prior to filling of this Information Disclosure Statement.					
	The	filir	ng of this Information Disclosure Statement shall not be construed as an					

admission that the information cited is, or is considered to be, material to patentability as defined

Information Disclosure Statement Serial No. 10/511,383 Attorney Docket: 22078-2 Page 3 of 4 # 439714

in §1.56(b). It is believed that no additional fees are required. Should any other fee be required, however, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

Respectfully submitted,

Kenneth A. Gandy, Reg. No. 33,386 Woodard, Emhardt Moriarty, McNett & Henry LLP

111 Monument Circle, Suite 3700 Indianapolis, Indiana 46204-5137

(317) 634-3456

439657 WEMMH PTO/SB/08a (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Origor the	T apolition ( Teaucada	ACLUL 18	ba, no persons are required	to respond to a collection of in	formation unless it contains a valid OMB control number		
Cub	atituta far farm 14	40/DTO		Complete if Known			
Sub	sulute for form 14	MATION DISCLOSURE MENT BY APPLICANT as many sheets as necessary)  Application Number 10/511,383  Filing Date October 14, 2004  First Named Inventor KLIBANOV, Alexander  Art Unit  Examiner Name					
				Filing Date	October 14, 2004		
ST	ATEMENT	BY A	PPLICANT	First Named Inventor	KLIBANOV, Alexander		
	(Use as many st	eets as	necessary)	Art Unit			
				Examiner Name			
Sheet	1	of	1	Attorney Docket No.	22078-2		

				U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1		r-Kind Code <sup>2</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or . Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-	4683092	07-28-1987	Tsang	
		US-	5464932	11-07-1995	Allcock et al.	
		US-	5578119	11-26-1996	Short et al.	
		US-	5846518	12-08-1998	Yan et al.	
_		us-	5869538	02-09-1999	Van Liew et al.	
		US-	6051207	04-18-2000	Klaveness et al.	
·		US-	6187288	02-13-2001	Schneider et al.	
		US-	6224554	05-01-2001	Tickner et al.	
		US-	6245318	06-12-2001	Klibanov et al.	
		US-	6372195	04-16-2002	Shutt et al.	
		US-	6416740	07-09-2002	Unger	
		US-	6443898	09-03-2002	Unger et al.	
		US-	6548048	04-15-2003	Cuthbertson et al.	
		US-				

		FO	REIGN PATEN	T DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		NON PA	TENT LITERA	TURE DOCUMENTS			
Examiner Initials*	Cite No.1						
PRICE ET AL., Delivery of Colloidal Particles and Red Blood Cells to Tissue Through Microvessel Ruptures Created by Targeted Microbubble Destruction With Ultrasound, Circulation, 29 September 1998, vol. 98, pages 1264-1267, see entire article.							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent document, the indication of the year of the reign of the emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>9</sup> Applicant is to place a check mark here if English language Translation is attached.

Considered

Signature